Ustekinumab for treating moderately to severely active ulcerative colitis in adults – Final Appraisal Document

In this DRAFT guidance ustekinumab is recommended to treat moderately to severely active ulcerative colitis when conventional therapy or a biological agent cannot be tolerated, only if a tumour necrosis factor-alpha inhibitor has failed, cannot be tolerated or is unsuitable.

Source:

National Institute for Health and Care Excellence